Cardiac Dysfunction - Prevention and Monitoring in Cancer Survivors
Key Points
Key Points
Heart failure (HF), presenting during or after completion of cancer treatment, is a well-recognized complication that begins with risk factors known to be associated with the development of HF, including the toxicity of chemotherapy and/or radiation (stage A), and is commonly progressive after structural changes to the heart occur.
The initial manifestation may be asymptomatic.
Onset may also be responsible for interruption or discontinuation of cancer-directed therapy, potentially reducing the chance for long-term survival.
Risk
...Ris...
...ended that cancer patients who meet any of the f...
...mendation can be made on the risk...
Prevention
...Prevention...
...Prevention P...
...id or minimize the use of potentially cardiotoxic...
...ans should perform a comprehensive assessme...
...Prevention D...
...icians should screen for and actively manage modif...
...ans may incorporate a number of strategi...
...require mediastinal RT which might impact car...
Surveillance
...Su...
...Monitorin...
...ns should complete a careful history and ph...
...commendation 4...
...or diagnostic work-up ( EB , H , B ,...
...c resonance imaging (MRI) or multi-gated acqu...
...c biomarkers (troponins, natriuretic...
...a cardiologist based on findings. (EB, B...
...tine surveillance imaging may be offered...
...ecommendations can be made regarding continuation...
...se routine echocardiographic surveillance in p...
...Monitoring After T...
...should complete a careful history and phy...
...commendation 5....
...or diagnostic work-up ( EB , H , B , M...
...or MUGA if echocardiogram is not available o...
...iac biomarkers (troponins, natriuretic pept...
Referral to a cardiologist based on find...
An echocardiogram may be performed 6–12 months a...
Cardiac MRI or MUGA may be offered for surveill...
...ied to have asymptomatic cardiac dysfunction d...
...ecommendations can be made regardi...
...should regularly evaluate and manage cardio...